Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

BACKGROUND: Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8...

Descripción completa

Detalles Bibliográficos
Autores principales: Montano, Ryan, Thompson, Ruth, Chung, Injae, Hou, Huagang, Khan, Nadeem, Eastman, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878047/
https://www.ncbi.nlm.nih.gov/pubmed/24359526
http://dx.doi.org/10.1186/1471-2407-13-604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878047/
https://www.ncbi.nlm.nih.gov/pubmed/24359526
http://dx.doi.org/10.1186/1471-2407-13-604

Ejemplares similares